Neurology News

The combination of intratumoral DNX-2401 and pembrolizumab appeared safe and provided “notable survival benefits” for select patients with recurrent glioblastoma, according to a study published in Nature Medicine.

Physicians listen to the patient in front of us. We care for one patient at a time. There is inherent individualization in the patient interaction. Each story is unique. Each treatment plan is tailored.

Consuming a pro-inflammatory diet was associated with higher risk for relapse and greater FLAIR lesion volume in the periventricular region in adults with MS, according to research in the Multiple Sclerosis Journal.

Adhering to a healthy plant-based diet for 3 years was associated with a reduced risk for cognitive impairment, but following an unhealthy plant-based diet was linked to a greater risk, according to recent study results.

Apellis Pharmaceuticals Inc. announced that its phase 2 MERIDIAN study investigating systemic pegcetacoplan as a treatment for ALS failed to meet efficacy measures of overall function, survival, lung function and muscle strength.

Since 2010, nearly $1 trillion has flooded the U.S. health care system, across multiple specialties, from private equity firms through thousands of deals to acquire hospitals and practices.

The FDA has granted conditional use with MRI to an implantable transvenous phrenic nerve stimulation therapy for adults with moderate to severe central sleep apnea.

Approximately one in four stroke survivors will experience a second stroke within 5 years, according to data from the American Stroke Association, yet research shows many patients still do not receive adequate follow-up and support.

BOSTON — The BrainPath device successfully surgically evacuated intracerebral hemorrhages in most patients enrolled in the ENRICH trial, Andrew Russman, DO, said in a Healio video during the American Academy of Neurology Annual Meeting.

Treatment with valbenazine at doses up to 80 mg once daily was generally well-tolerated and significantly improved chorea compared with placebo in adults with Huntington’s disease, according to research in The Lancet Neurology.